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Purpose: To evaluate short-term changes in central corneal endothelial cell density 
and morphology after photorefractive keratectomy (PRK) with mitomycin-C (MMC) 
0.02% in patients with moderate myopia.
Methods: In this prospective interventional case series, patients with moderate 
myopia (spherical equivalent refractive error from -4.0 to -8.0 D) underwent PRK 
with a single intraoperative application of MMC 0.02% for 40 seconds. Specular 
microscopy was performed preoperatively and repeated 6 months after surgery to 
determine changes in central corneal endothelial cell density (ECD), mean cell area 
(MCA) and coefficient of variation in cell size (CV).
Results: Overall, 42 eyes of 21 participants with mean age of 26.2±6.3 years underwent 
surgery. Mean preoperative spherical equivalent refractive error was -5.2±1.2 D 
which was reduced to -0.4±0.5 D postoperatively (P < 0.001). Mean ECD was reduced 
insignificantly from 2,920±363 cells/mm2 preoperatively to 2,802±339 cells/mm2 
postoperatively (P = 0.59). Similarly, there was no significant change in MCA or CV 
at six months (P = 0.76 and 0.52, respectively).
Conclusion: Application of MMC 0.02% for 40 seconds during PRK in patients with 
moderate myopia did not significantly affect central corneal endothelial cell density 
and morphology after a 6 month follow up period.
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INTRODuCTION
Mitomycin-C (MMC) was first isolated 
from cultures of Streptomyces caespitosus 
by Hata in 1956.1 Since then, it has been 
widely used intraoperatively for pterygium 
excision, trabeculectomy, and surface ablation 
keratorefractive procedures. Additionally, 
it is used topically in a cyclic fashion for 
primary or recurrent ocular surface squamous 
neoplasia.2 Having been found safe and 
effective in animals, MMC was suggested for 
application during surface ablation procedures 
to reduce postoperative haze formation.3,4 It can 
effectively reduce haze formation and hence, 
improve the predictability of visual outcomes 
following refractive surgery. Despite these 
advantages, MMC can potentially damage all 
three main corneal cell types including epithelial 
(differentiated epithelium and limbal cells), 
stromal (keratocytes), and endothelial cells. 
Several studies have investigated the effect 
of a single intraoperative dose of MMC during 
refractive surgery on the corneal endothelium. Endothelial cell loss after PRK with MMC; Zare et al
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Some clinical5,6 and laboratory7-9 studies have 
reported significant corneal endothelial toxicity. 
However, the majority of clinical studies have 
reported no significant change in corneal 
endothelial density or morphology with follow-
up period ranging from 3 to 18 months.10-15 
Most studies on MMC have employed a short 
duration of exposure, less than 20 seconds. 
Since different durations of MMC application 
have been used, discrepancies in the findings 
of these studies make it difficult to reach a 
definite conclusion regarding the safety of 
MMC for corneal endothelial cells.
Herein, we evaluate changes in central 
corneal endothelial cell density and morphology 
in a group of participants with moderate myopia 
after photorefractive keratectomy with MMC 
application for 40 seconds.
METHODS
This prospective interventional case series 
included 42 eyes of 21 patients (16 female 
subjects) aged 18 to 46 years with moderate 
myopia (spherical equivalent, -4.0 to -8.0 D). 
Contraindications for refractive surgery, such 
as severe dry eye, untreated blepharitis, corneal 
scarring, keratoconus, corneal dystrophy or 
degeneration, lens opacity, glaucoma, or retinal 
diseases, were considered as exclusion criteria. 
Additionally, history of ocular trauma or surgery 
led to patient exclusion. The Ethics Committee 
approved the study and informed consent was 
obtained from all participants after explaining 
the purpose of the study.
Preoperative evaluations included a case 
history, measurement of uncorrected visual 
acuity (UCVA) and best spectacle-corrected 
visual acuity (BSCVA) using the Snellen 
chart, manifest and cycloplegic refraction, 
slitlamp examination of the anterior segment, 
dilated fundus examination, measurement of 
intraocular pressure, central corneal pachymetry 
using an ultrasonic contact probe (A/B scan; 
Sonomed Inc., Lake Success, NY, USA), and 
corneal topography (Orbscan II, Orbtech, 
Bausch & Lomb, Rochester, NY, USA). Specular 
microscopy was also performed (SP 2000P, 
Topcon Inc., Tokyo, Japan) to determine central 
corneal endothelial cell density (ECD), mean 
cell area (MCA), and coefficient of variation 
in cell size (CV). To reduce sampling error, 
the clearest specular image containing at least 
100 endothelial cells in the center of the field 
was used.16 
Surgical Technique
All participants were operated on by a single 
ophthalmologist (MRJ) in a private practice 
setting, using a flying spot excimer laser 
machine (Technolas 217z, Bausch & Lomb 
Surgical, Rochester, NY, USA), with an emission 
wavelength of 193 nm, fixed pulse repetition rate 
of 50 Hz, and radiant exposure of 400 mJ. Topical 
tetracaine hydrochloride 0.5% eye drops were 
used to anesthetize the cornea. Antisepsis was 
performed by applying 10% povidone-iodine 
solution to the skin of the eyelids and periocular 
area for 1 minute and the eyes were washed 
out by 20 mL of balanced salt solution (BSS). 
The epithelium was mechanically removed in 
the 8.0 mm central cornea. Thereafter, ablation 
was performed using the Planoscan software 
(Bausch & Lomb, Rochester, NY, USA). Optical 
zone was 6.0 mm and manifest refractive error 
was considered as the target for correction in 
all cases. Subsequently, a sponge, 7.0 mm in 
diameter, soaked with mitomycin-C 0.02% 
(0.2 mg/mL, diluted in BSS), was applied 
over the ablated surface for 40 seconds. This 
was followed by copious irrigation with BSS, 
and fitting a contact lens (OmniFlex; Hydron, 
Fareham, UK) at the conclusion of the operation. 
Follow-up
Postoperatively, all participants were given 
chloramphenicol 0.5% eye drops every 6 hours 
for 1 week. Betamethasone 0.1% eye drops were 
initially administered twice a day until complete 
corneal reepithelialization. Thereafter, the dose 
was increased to four times a day for the next 
2 weeks and then gradually tapered over 6 
weeks. Once corneas completely reepithelialized 
(usually between 3 to 5 days), the contact lens 
was removed. 
Follow-up examinations were scheduled Endothelial cell loss after PRK with MMC; Zare et al
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1, 3, 7, and 30 days and 1, 3, and 6 months 
postoperatively. At each examination except 
on days 1 and 3, UCVA, BSCVA, manifest 
refraction, and tonometry were checked. 
Specular microscopy was repeated 6 months 
after surgery.
Statistical Analysis
Data were presented as mean ± standard 
deviation. Paired t-test was used to compare 
pre- and postoperative refractive error, ECD, 
MCA, and CV. Multiple linear regression 
analysis was performed to investigate whether 
the amount of correction and ablation depth had 
any correlation with reduction in postoperative 
ECD. P-values less than 0.05 were considered 
as statistically significant. 
RESuLTS
Forty-two eyes of 21 patients with mean age 
of 26.2±6.3 (range, 18 to 46) years underwent 
surgery. Mean preoperative spherical equivalent 
refractive error was -5.2±1.2 (range, -4.0 to 
-8.0) D which was reduced to -0.4±0.5 (range, 
-1.25 to +0.5) D postoperatively (P<0.001). There 
was no significant difference between pre- and 
postoperative BSCVA (0.05±0.13 logMAR and 
0.04±0.14 logMAR, respectively; P=0.57). Mean 
preoperative central corneal thickness and 
ablation depth were 569.4±38.5 (range, 497 to 
653) μm and 98.9±19.7 (range, 63.4 to 122) μm 
respectively. Six months after the operation, 
mean ECD was reduced by 4.0% (P=0.59) 
from 2,920±363 (range, 2,079 to 3,893) cells/
mm2 preoperatively, to 2,802±339 (range, 2,113 
to 3,434) cells/mm2. The average difference 
between pre- and postoperative ECD was 
29.47±296.2 (range, -537.0 to 775.0) cells/
mm2. Ten out of 42 eyes (23.8%) experienced 
reduction exceeding 100 cells/mm2, while 11 
eyes (26.2%) had an increase of 100 cells/mm2 
or more. There was no significant difference 
between these two subgroups in terms of 
preoperative refractive error, central corneal 
thickness, or ablation depth. There was no 
significant change in MCA [352±54 (range, 
256 to 530 μm2) preoperatively versus 362±45 
(range, 291 to 473 μm2) postoperatively, P=0.76] 
or CV [22.2±6.8 (range, 11 to 38) vs. 23.5±4.6 
(range, 15 to 31), P=0.52]. Multiple regression 
analysis revealed no significant correlation 
between reduction in ECD and ablation depth 
(P=0.75) or spherical equivalent refractive error 
(P=0.20).  
None of the patients developed postoperative 
complications such as persistent epithelial 
defect, infectious keratitis, or significant 
haze formation. Additionally, enhancement 
procedures for residual refractive errors were 
not required in any of the participants.
DISCuSSION
In the current study, reduction in cell density 
was 4.0%, which is exactly similar to a 4.1% 
variation previously observed in repeated 
measurements of endothelial cells in non-
operated eyes.17 Furthermore, 26.2% of the 
patients experienced an increase of 100 cells/
mm2 or more in endothelial cell counts which 
may be attributed to variations observed 
in repeated measurements. There was no 
significant change in the morphological features 
of the endothelial cells including mean cell 
area and coefficient of variation in cell size. 
The results of this study are supported by 
many others reporting no measurable effect on 
endothelial cell density or morphology after a 
single intraoperative application of MMC 0.02% 
ranging from 12 seconds to 2 minutes during 
surface ablation. Evaluating retrospectively a 
large number of eyes undergoing PRK with 
MMC 0.02%, Lee et al10 found that endothelial 
cell density remained unchanged after 16 
months. In a prospective interventional study, 
Zhao et al15 found no significant change in 
central endothelial cell density or morphology 
at least 6 months after a 15 second application 
of MMC 0.02%. Additionally, they did not 
observe any significant correlation between 
ablation depth and changes in endothelial 
cell density or morphology. Another study 
comparing ECD after LASEK with or without 
MMC 0.02% application for 30 seconds, showed 
no significant difference between the two 
groups.12 Similarly, other prospective studies Endothelial cell loss after PRK with MMC; Zare et al
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applying MMC 0.02% after surface ablation 
reported no significant change in cell density 
or morphology with follow-up ranging from 
3 to 18 months.11-15
In contrast, there are two studies associating 
MMC use with significant corneal endothelial 
cell loss. Morales et al5 conducted a randomized 
clinical trial on 18 eyes of 9 participants with 
myopia between -1.75 and -6.25 D. Fellow 
eyes were randomly assigned to PRK with 
MMC 0.02% or BSS for 30 seconds, the authors 
reported a significant reduction in endothelial 
cell count at month 1 (14.7%) and month 3 
(18.2%) in the MMC group, while corresponding 
figures were not significantly changed in the 
BSS group (4.3% and 5.0%, respectively). The 
sample size in the mentioned study was too 
small to draw a conclusive result. In another 
prospective non-randomized study, Nassiri et 
al6 used MMC 0.02% for 10 to 50 seconds in 
eyes undergoing PRK with an ablation depth 
of 75 μm or more and observed a significant 
decrease in central endothelial cell density. This 
decrease, which was documented during the 
first postoperative week, continued at a slower 
pace up to 6 months. Additionally, the authors 
reported the duration of MMC application and 
male sex to be significantly associated with 
greater endothelial cell loss. 
The clinical significance of the results of 
these two studies5,6 and laboratory studies7-9 
documenting MMC toxicity for endothelial 
cells is not clear as there is no report of corneal 
decompensation after surface ablation and 
MMC application since it was introduced for 
refractive surgery in 1991. Although there are 
case reports describing corneal decompensation 
with MMC,18-21 mainly after glaucoma surgery 
or phototherapeutic keratectomy, at least 
one reason other than MMC application was 
present for the compromised endothelium 
in each report, including previous cataract 
and glaucoma surgery,18 chronic uveitis19, 
high intraocular pressure,19,20 or complicated 
surgery21. Therefore, it remains unclear whether 
the corneal decompensation was caused by the 
use of mitomycin-C per se. 
The decrease in keratocyte density after 
MMC application is correlated with its 
concentration and to a lesser extent exposure 
time.22 A similar association can be expected 
for the effect of MMC on endothelial cells. 
Theoretically, another determinant could be 
the depth of ablation; deeper ablation leaves 
a thinner residual stroma, allowing the drug 
to penetrate and concentrate in the anterior 
chamber to a higher concentration. However, 
MMC 0.02% has been applied for 12 seconds to 
2 minutes after surface ablation, depending on 
ablation depth, and has been found to be safe for 
endothelial cells. The results of the current study 
show that the amount of correction and hence, 
ablation depth had no significant correlation 
with ECD. This observation is supported 
by the results of Zhao et al15. Therefore, the 
conventional residual stromal thickness set 
to prevent iatrogenic keratectasia (> 300 μm) 
seems to be enough to protect the endothelium 
against the adverse effects of topical MMC. 
In summary, this study demonstrated that 
intraoperative application of MMC 0.02% for 
40 seconds in a group of participants with 
moderate myopia did not adversely affect 
endothelial cell density and morphology up 
to 6 months.
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